Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels - PubMed (original) (raw)

Comparative Study

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels

Hiroaki Fukumoto et al. Arch Neurol. 2003 Jul.

Abstract

Background: Plasma amyloid beta-protein Abeta42 levels are increased in patients with familial Alzheimer disease (AD) mutations, and high levels reportedly identify individuals at risk to develop AD.

Objectives: To determine whether there are characteristic changes in plasma Abeta40 and Abeta42 levels in sporadic AD, and to examine the relationship of plasma Abeta measures with clinical, demographic, and genetic variables in a prospectively characterized outpatient clinic population.

Patients: A total of 371 outpatients with sporadic AD (n = 146), mild cognitive impairment (n = 37), or Parkinson disease (n = 96) and nondemented control cases (n = 92).

Methods: We collected plasma samples and determined Abeta40 and Abeta42 levels by sandwich enzyme-linked immunosorbent assay with the use of the capture antibody BNT77 (anti-Abeta11-28) and the detector antibodies horseradish peroxidase-linked BA27 (anti-Abeta40) and BC05 (anti-Abeta42).

Results: Mean Abeta40 and Abeta42 levels increased significantly with age in each diagnostic group. When covaried for age, mean plasma levels of Abeta40 and Abeta42 did not differ significantly among the 4 diagnostic groups. Within the mild cognitive impairment and AD groups, Abeta40 and Abeta42 levels did not correlate with duration of memory impairment or with cognitive test scores. The Abeta measures were not influenced by family history of AD, apolipoprotein E genotype, or current medication use of cholinesterase inhibitors, vitamin E, statins, nonsteroidal anti-inflammatory drugs, or estrogen.

Conclusions: Plasma Abeta measures increase with age, but, in contrast to reports on familial AD, plasma Abeta measures were neither sensitive nor specific for the clinical diagnosis of mild cognitive impairment or sporadic AD.

PubMed Disclaimer

Cited by

Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging.
Farvadi F, Hashemi F, Amini A, Alsadat Vakilinezhad M, Raee MJ. Farvadi F, et al. Int J Mol Cell Med. 2023;12(2):172-210. doi: 10.22088/IJMCM.BUMS.12.2.172. Int J Mol Cell Med. 2023. PMID: 38313372 Free PMC article. Review.
Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele.
Sun X, Chiu CC, Liebson E, Crivello NA, Wang L, Claunch J, Folstein M, Rosenberg I, Mwamburi DM, Peter I, Qiu WQ. Sun X, et al. Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):238-44. doi: 10.1097/WAD.0b013e31819cb3ac. Alzheimer Dis Assoc Disord. 2009. PMID: 19812466 Free PMC article.
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
Bateman RJ, Klunk WE. Bateman RJ, et al. Neurotherapeutics. 2008 Jul;5(3):381-90. doi: 10.1016/j.nurt.2008.05.009. Neurotherapeutics. 2008. PMID: 18625449 Free PMC article. Review.
Amyloid-associated depression: a prodromal depression of Alzheimer disease?
Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ. Sun X, et al. Arch Gen Psychiatry. 2008 May;65(5):542-50. doi: 10.1001/archpsyc.65.5.542. Arch Gen Psychiatry. 2008. PMID: 18458206 Free PMC article.
Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
de Kort AM, Kuiperij HB, Jäkel L, Kersten I, Rasing I, van Etten ES, van Rooden S, van Osch MJP, Wermer MJH, Terwindt GM, Schreuder FHBM, Klijn CJM, Verbeek MM. de Kort AM, et al. Alzheimers Res Ther. 2023 Jun 3;15(1):102. doi: 10.1186/s13195-023-01245-2. Alzheimers Res Ther. 2023. PMID: 37270536 Free PMC article.

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels - PubMed (original) (raw)